Psilocybin for Weight Loss? New Study Says the Trip Isn't the Medicine
- Sascha Kuhlmann
- 17 hours ago
- 4 min read
An Italian study shows low-dose psilocybin reversed obesity, diabetes, and fatty liver in mice. Not through the brain. Through the liver.
Most people assume psilocybin works because of the trip. The mystical experience. The ego dissolution. The neural rewiring that comes from seeing reality without filters for a few hours.
What if the mushroom is doing something your conscious mind never notices?
A study published in February 2026 in Pharmacological Research found that sub-psychedelic doses of psilocybin reversed obesity, type 2 diabetes, and fatty liver disease in mice. The mechanism has nothing to do with the psychedelic experience.
Zero trip. Zero brain involvement. The medicine was working in the liver.
The study
Researchers from the University of Padua and the University of Milan fed mice a high-fat, high-sugar diet for 12 weeks. Think standard American diet. One group received chronic low-dose psilocybin (0.05 mg/kg), roughly equivalent to a microdose in humans.
The results:
Weight gain dropped. Not because they ate less. They didn't.
Insulin sensitivity improved and blood sugar normalized.
Fatty liver disease reversed. Visible improvements in liver tissue.
Muscle strength preserved. The mice actually got stronger.
Pancreatic beta cells repaired. The insulin-producing cells damaged by the bad diet started recovering.
None of this triggered detectable effects on the central nervous system. The mice weren't tripping. They weren't experiencing altered consciousness. Their brains showed no psychedelic activity.
What was actually happening?
A different receptor, a different pathway
This is where it gets interesting for anyone who microdoses.
Psilocybin's psychedelic effects come from the 5-HT2A serotonin receptor in the brain. That's the one responsible for visual distortions, ego dissolution, and the mystical experiences that clinical trials study for depression and PTSD.
The metabolic benefits in this study came from a different receptor entirely: 5-HT2B, located in the liver.
The researchers confirmed this using CRISPR gene editing on human liver cells. When they knocked out the 5-HT2B receptor, the metabolic benefits disappeared. When they knocked out 5-HT2A (the psychedelic receptor), the benefits remained.
In other words: the liver benefits are independent of the trip.
These data challenge the idea that the therapeutic potential of psilocybin is necessarily linked to the psychedelic experience. At chronic low doses, psilocybin acts as a peripheral modulator of metabolism, particularly at the liver level, through a distinct serotonergic pathway.
— Sara De Martin, University of Padua
Why this matters for the microdosing conversation
If you're part of the microdosing community, you've probably heard the skeptics: "There's no evidence microdosing does anything. It's all placebo." And honestly, the clinical evidence for sub-perceptual dosing has been thin — most studies focus on full psychedelic doses.
This study shifts that conversation. Not because it proves microdosing cures obesity. It doesn't. It's a mouse study. What it does is demonstrate a clear biological mechanism for sub-psychedelic psilocybin. The compound is doing something real at the cellular level, even when the dose is too low to produce any conscious experience.
The full story of what psilocybin does in the body is bigger than what happens between your ears.
The muscle-sparing angle
This detail deserves its own section.
One of the biggest criticisms of GLP-1 drugs like Ozempic and Wegovy is muscle loss. People lose weight, yes. They also lose significant muscle mass. The medical community calls this sarcopenic obesity risk, and it's a real concern for long-term health outcomes.
The psilocybin-treated mice showed the opposite pattern. Their muscle strength and function actually improved, likely through restored leptin sensitivity. The researchers call psilocybin a muscle-sparing, CNS- and cardio-safe drug candidate for metabolic conditions.
Early days. Still, the contrast with current weight-loss drugs is hard to ignore.
What we don't know yet
This is a mouse study. I need to be clear about that.
Mice are not humans. The dose translation from mouse to human isn't straightforward. Allometric scaling suggests 0.05 mg/kg in mice lands somewhere in microdose territory for humans. "Somewhere" isn't precise enough for medical guidance.
We also don't know:
Whether these effects replicate in humans
What happens with longer treatment periods
Whether there are side effects that didn't show up in 12 weeks
How this interacts with other medications
Several of the study's authors have financial ties to Relmada Therapeutics, a company developing psilocybin for metabolic applications. The study was published in a peer-reviewed journal and the methodology looks solid. Still, commercial motivation behind a line of research is context worth knowing.
The bigger picture
For years, psychedelic research has been laser-focused on mental health: depression, PTSD, anxiety, addiction. Those applications matter and the evidence keeps growing. This study says psilocybin's story is much bigger than brain chemistry.
The fungal tryptamine is a whole-body molecule. It interacts with serotonin receptors throughout the body: the liver, the gut, muscle tissue, the pancreas. We've been so focused on what it does to consciousness that we may have missed what it does to metabolism.
If human trials confirm what the mice are telling us, we might look back at this study as the moment psychedelic medicine expanded beyond the mind.
The paper
Title: "Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms"
Authors: Colognesi M, Gabbia D, Signor A, et al.
Journal: Pharmacological Research, Volume 224, February 2026
Full text: ScienceDirect (open access)
This article is for educational purposes only. It is not medical advice. Psilocybin remains a Schedule I substance under federal law in the United States. Always consult a healthcare professional before making decisions about your health.
Curious about psychedelic integration?
If you've had a psychedelic experience and want help making sense of it, Adult in Training offers integration coaching for men. Grounded, practical, judgment-free. Sliding scale available.
Comments